Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis

• Published in: BMC pediatrics Vol. 16; no. 1; p. 75
• Main Authors: Siegfried, Elaine C., Jaworski, Jennifer C., Kaiser, Jennifer D., Hebert, Adelaide A.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.06.2016; BioMed Central
• Subjects: Administration, Cutaneous; Adrenal Cortex Hormones - adverse effects; Adrenal Cortex Hormones - therapeutic use; Asthma; Atopic dermatitis; Atrophy; Calcineurin Inhibitors - adverse effects; Calcineurin Inhibitors - therapeutic use; Case reports; Child; Clinical trials; Complications and side effects; Corticosteroids; Dermatitis; Dermatitis, Atopic - drug therapy; Dermatologic Agents - adverse effects; Dermatologic Agents - therapeutic use; Dosage and administration; Drug therapy; Eczema; FDA approval; Humans; Lymphoma; Meta-analysis; Pediatrics; Rhinitis; Skin diseases; Steroids; Tacrolimus; Treatment Outcome; United States; United States > US; Pimecrolimus; Tacrolimus; Topical corticosteroid; Atopic dermatitis; TCS; Long-term safety; TCI; Lymphoma; Pediatric; Topical calcineurin inhibitor

Many clinicians have concerns about the safety of atopic dermatitis (AD) treatments, particularly in children requiring long-term daily maintenance therapy. Topical corticosteroids (TCS) have been widely used for >5 decades. Long-term TCS monotherapy has been associated with adverse cutaneous eff...